Maintenance Therapy With Tyrosine Kinase Inhibitors After Transplant in Patients With Chronic Myeloid Leukemia

Restricted access

Because of their outstanding efficacy and low toxicity, tyrosine kinase inhibitors (TKIs) have replaced allogeneic hematopoietic cell transplant (HCT) as the standard frontline therapy for patients with newly diagnosed chronic myeloid leukemia (CML). Until a decade ago, HCT was the preferred treatment for CML, with 5-year overall survival rates of approximately 80%, 40%, and 20% for patients in chronic, accelerated, and blast crisis phases, respectively. Relapse after transplant is a problem for patients who undergo transplant in advanced phase disease and those undergoing a T-depleted transplant. Until the introduction of TKIs, therapy for relapsed CML after transplant relied on interferon and/or donor leukocyte infusion (DLI). Although effective in inducing remission, DLI is associated with clinically significant graft-versus-host disease or myelosuppression, with an accompanying treatment-related mortality of 5% to 20%. TKIs have emerged as an attractive alternative therapy for persistent or relapsing CML after HCT. Similar to DLI, the effectiveness of TKI posttransplant is largely determined by the phase of disease at relapse, showing very good response in patients experiencing relapse in the chronic phase, with high rates (>60%) of hematologic and cytogenetic remissions, but less favorable outcomes in patients with advanced disease, with only a minority experiencing durable cytogenetic or molecular remissions. Molecular monitoring of the BCR-ABL chimeric mRNA posttransplant is important for early detection of patients at high risk of relapse.

Correspondence: Jerald Radich, MD, Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4-100, Seattle, WA 98109. E-mail: jradich@fhcrc.org
  • 1.

    Druker BJ, Guilhot F, O’Brien SG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:24082417.

    • Search Google Scholar
    • Export Citation
  • 2.

    Kantarjian H, Shah NP, Hochhaus A. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:22602270.

    • Search Google Scholar
    • Export Citation
  • 3.

    Saglio G, Kim DW, Issaragrisil S. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:22512259.

  • 4.

    Davies SM, DeFor TE, McGlave PB. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339346.

    • Search Google Scholar
    • Export Citation
  • 5.

    Hansen JA, Gooley TA, Martin PJ. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962968.

    • Search Google Scholar
    • Export Citation
  • 6.

    Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17(Suppl 3):S56.

    • Search Google Scholar
    • Export Citation
  • 7.

    Gratwohl A, Hermans J, Goldman JM. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:10871092.

    • Search Google Scholar
    • Export Citation
  • 8.

    Pavlu J, Kew AK, Taylor-Roberts B. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 2010;115:40184020.

    • Search Google Scholar
    • Export Citation
  • 9.

    Goldman JM, Majhail NS, Klein JP. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010;28:18881895.

    • Search Google Scholar
    • Export Citation
  • 10.

    Gratwohl A, Brand R, Apperley J. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513521.

    • Search Google Scholar
    • Export Citation
  • 11.

    Boehm A, Walcherberger B, Sperr WR. Improved outcome in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single center experience. Biol Blood Marrow Transplant 2011;17:133140.

    • Search Google Scholar
    • Export Citation
  • 12.

    Saussele S, Lauseker M, Gratwohl A. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010;115:18801885.

    • Search Google Scholar
    • Export Citation
  • 13.

    Beelen DW, Graeven U, Elmaagacli AH. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995;85:29812990.

    • Search Google Scholar
    • Export Citation
  • 14.

    Goldman JM, Szydlo R, Horowitz MM. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993;82:22352238.

    • Search Google Scholar
    • Export Citation
  • 15.

    Morton AJ, Gooley T, Hansen JA. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998;92:394401.

    • Search Google Scholar
    • Export Citation
  • 16.

    Deininger M, Schleuning M, Greinix H. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006;91:452459.

    • Search Google Scholar
    • Export Citation
  • 17.

    Oehler VG, Gooley T, Snyder DS. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007;109:17821789.

    • Search Google Scholar
    • Export Citation
  • 18.

    Lee SJ, Kukreja M, Wang T. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008;112:35003507.

    • Search Google Scholar
    • Export Citation
  • 19.

    Nicolini F, Modolo L, Raus N. Allogeneic stem cell transplantation for blast crisis (BC) chronic myelogenous leukemia (CML) in the tyrosine kinase inhibitors (TKIs) era. analysis of pre-transplant variables on transplant outcome. on behalf of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML [abstract]. Blood 2010;116:Abstract 2266.

    • Search Google Scholar
    • Export Citation
  • 20.

    Roth M, Antin J, Ash R. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992;79:276282.

    • Search Google Scholar
    • Export Citation
  • 21.

    Delage R, Soiffer R, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991;78:27592767.

    • Search Google Scholar
    • Export Citation
  • 22.

    Radich JP, Gehly G, Gooley T. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995;85:26322638.

    • Search Google Scholar
    • Export Citation
  • 23.

    Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996;17:643647.

    • Search Google Scholar
    • Export Citation
  • 24.

    Olavarria E, Kanfer E, Szydlo R. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97:15601565.

    • Search Google Scholar
    • Export Citation
  • 25.

    Radich JP, Gooley T, Bryant E. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood 2001;98:17011707.

    • Search Google Scholar
    • Export Citation
  • 26.

    Kantarjian HM, O’Brien S, Cortes JE. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100:15901595.

    • Search Google Scholar
    • Export Citation
  • 27.

    Olavarria E, Ottmann OG, Deininger M. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:17071712.

    • Search Google Scholar
    • Export Citation
  • 28.

    Dazzi F, Szydlo RM, Cross NC. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000;96:27122716.

    • Search Google Scholar
    • Export Citation
  • 29.

    Kolb HJ, Schattenberg A, Goldman JM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:20412050.

    • Search Google Scholar
    • Export Citation
  • 30.

    Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123137.

    • Search Google Scholar
    • Export Citation
  • 31.

    Michallet AS, Nicolini F, Furst S. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 2005;35:601608.

    • Search Google Scholar
    • Export Citation
  • 32.

    Guglielmi C, Arcese W, Dazzi F. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002;100:397405.

    • Search Google Scholar
    • Export Citation
  • 33.

    Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant 2008;42:569579.

    • Search Google Scholar
    • Export Citation
  • 34.

    DeAngelo DJ, Hochberg EP, Alyea EP. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004;10:50655071.

    • Search Google Scholar
    • Export Citation
  • 35.

    Hess G, Bunjes D, Siegert W. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005;23:75837593.

    • Search Google Scholar
    • Export Citation
  • 36.

    Weisser M, Tischer J, Schnittger S. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006;91:663666.

    • Search Google Scholar
    • Export Citation
  • 37.

    Savani BN, Montero A, Kurlander R. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:10091015.

    • Search Google Scholar
    • Export Citation
  • 38.

    Wright MP, Shepherd JD, Barnett MJ. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:639646.

    • Search Google Scholar
    • Export Citation
  • 39.

    Klyuchnikov E, Kroger N, Brummendorf TH. Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML). Biol Blood Marrow Transplant 2010;16:301310.

    • Search Google Scholar
    • Export Citation
  • 40.

    Atallah E, Kantarjian H, De Lima M. The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT). Blood 2006;108:4520.

    • Search Google Scholar
    • Export Citation
  • 41.

    O’Connor LM, Langabeer S, McCann SR, Conneally E. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure. Bone Marrow Transplant 2008;42:833835.

    • Search Google Scholar
    • Export Citation
  • 42.

    Breccia M, Cannella L, Stefanizzi C. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? Bone Marrow Transplant 2009;44:331332.

    • Search Google Scholar
    • Export Citation
  • 43.

    Klyuchnikov E, Schafhausen P, Kroger N. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 2009;122:610.

    • Search Google Scholar
    • Export Citation
  • 44.

    Garland P, Dazzi F, Marin D. Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant 2010;45:395396.

    • Search Google Scholar
    • Export Citation
  • 45.

    Cortes JE, Pinilla-Ibarz J, le Coutre P. Efficacy and safety of ponatinib according to prior approved tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia in chronic phase (CP-CML): results from the PACE trial. Presented at the 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, Georgia. Abstract 3749.

    • Search Google Scholar
    • Export Citation
  • 46.

    Cortes JE, Kantarjian H, Shah NP. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:20752088.

  • 47.

    Palandri F, Amabile M, Rosti G. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 2007;39:189191.

    • Search Google Scholar
    • Export Citation
  • 48.

    Carpenter PA, Snyder DS, Flowers ME. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:27912793.

    • Search Google Scholar
    • Export Citation
  • 49.

    Olavarria E, Siddique S, Griffiths MJ. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007;110:46144617.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 77 65 7
PDF Downloads 58 49 9
EPUB Downloads 0 0 0